Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleximenib plus intensive chemotherapy for newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia
NL-OMON59173Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Bleximenib plus intensive chemotherapy with Placebo plus intensive chemotherapy (2 arms). Primary endpoint: Event-free survival. Started Jan 2026; status: recruiting.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON59173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59173.